GSK Advances Wave’s siRNA Program, Triggers $12M Milestone

  • GSK selected a hepatology siRNA program from Wave’s collaboration for further development.
  • Wave receives a $12M milestone payment, with up to $330–375M in additional milestones per program.
  • Three additional collaboration programs are advancing toward candidate selection.
  • Wave’s SpiNA siRNA technology is highlighted for superior pharmacology and potency.

This deal underscores the growing strategic importance of RNA-based therapeutics in drug development, particularly in hepatology. Wave’s ability to leverage its PRISM platform and human genetic insights positions it as a key player in the RNA medicines space, with GSK’s validation potentially attracting further partnerships. The financial upside, including milestone payments and royalties, highlights the high-stakes nature of biotech collaborations.

Pipeline Momentum
Whether Wave can sustain progress with its three additional collaboration programs.
Technology Validation
How GSK’s adoption of Wave’s SpiNA siRNA technology will impact competitive positioning.
Financial Upside
The pace at which Wave can convert collaboration milestones into revenue.